There is provided a method that can recover a cell having specific cell information, of cells having cell information that changes over time, from a cell group. A cell recovery method for recovering a specific cell from a cell group including a plurality of cells having cell information that changes over time includes (a) a step of detecting or measuring a desired indicator in each cell of the cell group along a time axis, and (b) a step of recovering a cell having undergone a predetermined change in the indicator, wherein the cell is recovered at a time point after elapse of a preset time since a time point of occurrence of a predetermined change in the indicator.

The present invention relates to the diagnosis and treatment of solar lentigo (SL). The inventors established an in vitro model of primary fibroblasts isolated from SL (FL) and perilesional (FS) biopsies, which were collected from a cohort of 10 volunteers. Then, the inventors defined morphological and functional characteristics of both dermal cells. The inventors demonstrated by immunofluorescence studies differential morphological features with FL displaying elongated shape, a thin epidermis, disorganized basement membrane, intense melanin deposition and elongated rete ridges collapsing into the dermis and FS presented flattened morphology. Moreover, both fibroblasts demonstrated distinct functional characteristics with FL exhibiting a lower proliferation rate and migration capacity, senescent-like phenotype as well as a higher ability to secrete KGF, HGF, SCF, IL-13 and TGF1. Thus, the present invention relates to a method of identifying a subject having or at risk of having or developing solar lentigo, comprising measuring the expression level of IL-13, TGF1, HGF, KGF and SCF. The present invention also relates to an IL-13 inhibitor compound for use in the treatment of solar lentigo.

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Provided are various embodiments relating to IL13R/IL4R contiguous polypeptides and IL13R/IL4R heterodimeric proteins from companion animal species and that bind to IL13 and/or IL4, including long-acting contiguous polypeptides and heterodimeric proteins. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.

Methods of detecting and quantifying IL-13 are provided. Also provided are methods of diagnosing, selecting and identifying patients with Th2-associated diseases (Type 2-associated diseases) for treatment with certain therapeutic agents that are Th2 pathway inhibitors (Type 2 pathway inhibitors).

The present invention provides methods, compositions, and kits for the treatment and/or diagnosis of psoriasis. The invention includes a method for diagnosing psoriasis, comprising measuring a level or combination of levels of one or more of: IL-5, IL-6, IL-7, IL-10, IL-13, IL-33, FGF-B, GMCSF, VEGF, IL-33, MCP-1, or IP-10, or combinations thereof, in a sample from a patient; comparing said measured level or combination of levels; and correlating said level or combination of levels with a manifestation of psoriasis within said patient. A medicinal composition comprising an herbal combination of Da Huang, Sheng Di Huang, and Jin Yin Hua for the treatment of psoriasis in a patient. A kit for diagnosing and/or prognosing psoriasis in a patient.

The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery.

The disclose relates to adenomas of the colon. More particularly, the present disclosure relates to biomarkers which may be used for the detection of advanced colorectal pre-cancerous adenomas (APA) The detection and measurement of these biomarkers in a biological sample may be used to inform the clinician as to whether further invasive procedures such as polypectomy are required.

The method for diagnosing sleep apnea includes measuring concentrations of biomarkers in a patient's bodily sample. To determine whether a patient suffers from sleep apnea, or has a predisposition for developing sleep apnea, a sample from the patient is analyzed. If one or more of the following biomarker concentrations are found in the patient's sample, then the patient may be diagnosed as suffering from sleep apnea or having a predisposition for developing sleep apnea: between approximately 992.8 pg/mL and approximately 1309.6 pg/mL of adipsin; between approximately 1,640 pg/mL and approximately 2,900 pg/mL of betatrophin; between approximately 8,090.82 pg/mL and approximately 11,829.07 pg/mL of brain-derived neurotrophic factor (BDNF); between approximately 11.82 pg/mL and approximately 88.26 pg/mL of interleukin-13 (IL-13); between approximately 49.45 pg/mL and approximately 103.29 pg/mL of tumor necrosis factor- (TNF-); and between approximately 16.55 pg/mL and approximately 29.76 pg/mL of the protein encoded by Human DNAJC27.